scispace - formally typeset
Open AccessJournal ArticleDOI

Atypical Hemolytic Uremic Syndrome

TLDR
HUS is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure that predicts the prognosis both in native kidneys and after renal transplantation.
About
This article is published in Seminars in Nephrology.The article was published on 2013-11-01 and is currently open access. It has received 258 citations till now. The article focuses on the topics: Atypical hemolytic uremic syndrome & Eculizumab.

read more

Citations
More filters
Journal ArticleDOI

Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission

TL;DR: Serum samples from patients in remission showed normal in vitro patterns of complement activation and demonstrated normal kinetics of complementactivation in the fluid phase, providing important insight into complement regulation in aHUS.
Journal ArticleDOI

The genetics of atypical hemolytic uremic syndrome.

TL;DR: The genetic background of aH US, the role of complement for aHUS pathogenesis, and the different groups of specific mutations known to be involved in the pathogenesis are discussed.
Journal ArticleDOI

Pediatric Antiphospholipid Syndrome

TL;DR: The purpose of this report is to review the current literature on APS in children and neonates, identify the gaps in current knowledge, and suggest avenues for studies to fill those gaps.
References
More filters
Journal ArticleDOI

Complement: a key system for immune surveillance and homeostasis

TL;DR: An updated view of the function, structure and dynamics of the complement network is described, its interconnection with immunity at large and with other endogenous pathways is highlighted, and its multiple roles in homeostasis and disease are illustrated.
Journal ArticleDOI

Atypical Hemolytic–Uremic Syndrome

TL;DR: Current concepts about the pathobiology of atypical hemolytic–uremic syndrome are reviewed and its diagnosis and management are reviewed.
Journal ArticleDOI

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

TL;DR: The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Related Papers (5)